October 2024 in “Acta Biomaterialia” Collagen makes skin stiff, and preservation methods greatly increase tissue stiffness.
March 2024 in “Organic letters” A new method efficiently modifies alkenes to create useful medicinal compounds.
February 2024 in “International journal of molecular sciences” Type 3 Innate Lymphoid Cells help maintain skin health and balance, and are involved in skin diseases and healing.
January 2024 in “Biomedicines” Using stem cells from hair follicles to treat female hair loss is safe and effective after six months.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
June 2023 in “Stem cell reviews and reports” Stem cell therapies could be a promising alternative for hair loss treatment, but more research is needed to understand their full potential and safety.
May 2023 in “IntechOpen eBooks” More research is needed to understand how testosterone is maintained in adult males.
February 2023 in “Frontiers in Bioengineering and Biotechnology” Optical imaging and light therapy show promise for diagnosing and treating liver injury caused by surgery.
April 2021 in “IntechOpen eBooks” Androgens, male hormones, affect physical and mental functions, with a decrease leading to health issues like muscle loss, bone disease, and depression, and more research is needed on long-term effects and treatments.
October 2020 in “Authorea (Authorea)” Men and women react differently to opioids, with hormones potentially influencing these differences.
June 2013 in “International Journal of Dermatology” Central lipohypertrophy in HIV-infected women may lead to shorter eyelashes.
April 2023 in “Dermatology and therapy” Most patients stop using topical minoxidil due to side effects.
Stem cell treatments show promise for hair loss but need more research.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
January 2016 in “Medicinski Podmladak”